Vericiguat in Heart Failure with Reduced Ejection Fraction REPLY

被引：0
|
作者：
Armstrong, Paul W. [1 ]
Anstrom, Kevin J. [2 ]
O'Connor, Christopher M. [3 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Duke Clin Res Inst, Durham, NC USA
[3] Inova Heart & Vasc Inst, Falls Church, VA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1498
页数：2
相关论文
共 50 条
  • [21] Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Hauke Ruehs
    Dagmar Klein
    Matthias Frei
    Joachim Grevel
    Rupert Austin
    Corina Becker
    Lothar Roessig
    Burkert Pieske
    Dirk Garmann
    Michaela Meyer
    [J]. Clinical Pharmacokinetics, 2021, 60 : 1407 - 1421
  • [22] Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat
    Andrew J. S. Coats
    Heli Tolppanen
    [J]. Drugs, 2021, 81 : 1599 - 1604
  • [23] Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
    Nakamura, Makiko
    Imamura, Teruhiko
    Kinugawa, Koichiro
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [24] Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Ruehs, Hauke
    Klein, Dagmar
    Frei, Matthias
    Grevel, Joachim
    Austin, Rupert
    Becker, Corina
    Roessig, Lothar
    Pieske, Burkert
    Garmann, Dirk
    Meyer, Michaela
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (11) : 1407 - 1421
  • [25] EJECTION FRACTION, BIOMARKERS, AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION AND THE IMPACT OF VERICIGUAT ON OUTCOMES IN THE VICTORIA TRIAL
    Butler, Javed
    Zheng, Yinggan
    Bonderman, Diana
    Lund, Lars
    DeFilippi, Christopher R.
    Blaustein, Robert
    Ezekowitz, Justin A.
    Freitas, Cecilia
    Hernandez, Adrian F.
    O'Connor, Christopher M.
    Voors, Adriaan
    Westerhout, Cynthia M.
    Lam, Carolyn S. P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 372 - 372
  • [26] Developments in Heart Failure With Reduced Ejection Fraction Reply
    Murphy, Sean P.
    Ibhrahim, Nasrien E.
    Januzzi, James L., Jr.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (21): : 2215 - 2216
  • [27] Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
    Oh, Jaewon
    Lee, Chan Joo
    Park, Jin Joo
    Lee, Sang Eun
    Kim, Min-Seok
    Cho, Hyun-Jai
    Choi, Jin-Oh
    Lee, Hae-Young
    Hwang, Kyung-Kuk
    Kim, Kye Hun
    Yoo, Byung-Su
    Choi, Dong-Ju
    Baek, Sang Hong
    Jeon, Eun-Seok
    Kim, Jae-Joong
    Cho, Myeong-Chan
    Chae, Shung Chull
    Oh, Byung-Hee
    Kang, Seok-Min
    [J]. ESC HEART FAILURE, 2022, 9 (02): : 1492 - 1495
  • [28] Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis
    Trujillo, Maria E.
    Arrington, Leticia
    Patel, Yogesh
    Passarell, Julie
    Wenning, Larissa
    Blaustein, Robert O.
    Armstrong, Paul W.
    Meyer, Michaela
    Becker, Corina
    Gheyas, Ferdous
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 1061 - 1069
  • [29] Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
    Gonzalez-Juanatey, Jose Ramon
    Comin-Colet, Josep
    Figal, Domingo Pascual
    Bayes-Genis, Antoni
    Cepeda, Jose Maria
    Garcia-Pinilla, Jose M.
    Garcia-Quintana, Antonio
    Manzano, Luis
    Zamorano, Jose Luis
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 839 - 849
  • [30] Vericiguat-new treatment option for patients with heart failure Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)
    Bauersachs, J.
    Nitschmann, S.
    [J]. INTERNIST, 2020, 61 (09): : 989 - 991
12345